Efficacy of noiiglutide injection on body weight in obese Chinese adults without diabetes: A multicentre, randomized, double‐blind, placebo‐controlled, phase 2 trial
Authors' conclusion
In obese Chinese adults without diabetes, once-daily subcutaneous noiiglutide significantly reduced body week at week 24 compared with placebo, and had a manageable safety profile, primarily involving gastrointestinal disorders.
Study context
- Population
- Obese Chinese adults without diabetes, BMI 28.0–40.0 kg/m²enrolled
- Participants
- 254 adults
- Comparison
- Noiiglutide vs placebo, adjunct to lifestyle intervention
- Primary endpoint
- Change in body weight from baseline
- Follow-up
- Week 24
Methodological detailsmulticentre, double-blind, placebo-controlled, phase 2, Randomized 1:1:1 to dose level, then 3:1 noiiglutide vs placebo within each dose level
- Multicentre
- Double-blind
- Placebo-controlled
- Phase 2
- Randomized 1:1:1 to dose level, then 3:1 noiiglutide vs placebo within each dose level
Primary result
As reported in the abstract
LS mean reduction in body weight · baseline to week 24
Placebo
3.65
least squares mean · kg
All p-values <.0001
- LS mean reduction across all noiiglutide doses
- 8.03 to 8.50 kg
Further findings
Weight loss ≥5%
Weight loss ≥10%
Weight loss ≥5%
- Significantly higher proportion with noiiglutide vs pooled placebo
Weight loss ≥10%
- Significantly higher proportion with noiiglutide vs pooled placebo
Safety
Gastrointestinal adverse events
- Nausea, all noiiglutide groups vs pooled placebo
- 15.4%-30.2% vs 8.1%
- Diarrhoea, all noiiglutide groups vs pooled placebo
- 18.8%-22.2% vs 6.5%
- Vomiting, all noiiglutide groups vs pooled placebo
- 15.6%-18.5% vs 0%
- More common in all noiiglutide groups
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Efficacy of noiiglutide injection on body weight in obese Chinese adults without diabetes: A multicentre, randomized, double‐blind, placebo‐controlled, phase 2 trial. Diabetes Obes Metab. Published 17 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →